Medtronic has today announced its entry into a definitive agreement to acquire Scientia Vascular. The acquisition—expected to close in the first half of the 2027 financial year (FY27)—is valued at US$550 million, subject to customary adjustments, with potential undisclosed earn-out and milestone payments post-acquisition.
A Medtronic press release states that, under founder and current chief technology officer John Lippert, Scientia has developed best-in-class access products that enable simplicity and access for physicians treating complex neurovascular conditions. Scientia’s portfolio of guidewires and catheters can be “seamlessly integrated” with Medtronic’s existing suite of neurovascular products, strengthening the latter company’s ability to support physicians across the full procedural workflow, the release adds.
“Medtronic is thrilled to acquire Scientia to accelerate meaningful innovation in neurovascular care,” said Linnea Burman, senior vice president and president of Medtronic’s neurovascular business, which is part of the company’s neuroscience portfolio. “This acquisition positions Medtronic with a full suite of products. It builds a strong foundation for Medtronic, and supports procedures across both haemorrhagic and acute ischaemic stroke. Medtronic’s best-in-class therapies—combined with Scientia’s leading access portfolio—will be incredibly powerful. With 12 million people globally suffering from stroke each year, we look forward to contributing to better patient outcomes around the world.”
Scientia’s novel platform is designed to address the many access-related challenges currently facing neurointerventional physicians by improving navigability through complex anatomy and simplifying neurovascular procedures. By enabling faster and more reliable access, these technologies improve procedural efficiency, Medtronic also claims.
“Microwires and microcatheters are required for all neurointerventional cases,” said David Fiorella (Stony Brook Medicine, Stony Brook, USA). “Correspondingly, better microwires and microcatheters make every single case technically easier, faster and ultimately safer for patients. This revolutionary microwire technology has enabled—and will continue to enable—access, and simplify the neurovascular procedures we do.”
“As a company committed to improving patients’ lives, we are humbled and excited for what’s ahead,” added Scientia chief executive officer (CEO) Rick Randall. “Scientia has developed critical technology that has been embraced by physicians. This deal allows us to take our engineering into disease states globally, and positions Medtronic with a comprehensive portfolio and complete guidewire line. With the size and scale of Medtronic, the opportunity to treat more patients and drive more impact is truly exciting.”
Medtronic’s release also notes that this acquisition is expected to be minimally dilutive to the company’s adjusted earnings per share (EPS) in FY27 and accretive thereafter.
